News

New treatments for geographic atrophy coming down the pike has the potential to change eye care providers' approach to identifying and managing the disease.

The prevailing message is that physicians have “a long way to go” in the optimization of management and prevention of myopic vitreoretinal disease.

iCRx is set to release the One Minute Eye Exam in April, potentially changing the way ophthalmologists and optometrists conduct eye examinations for corrective lenses.

Sruthi Arepalli, MD, discusses the case of a patient with syphilis and sheds light on the complexities of diagnosing a masquerading syndrome.

Marsha Link, PhD, uses three words—Imagine, Prepare, and Optimize—to encourage women to assess their current leadership journey, strategically plan for advancement, and explore new opportunities for growth and impact in vision care.

The 2024 EnVision Summit will feature a brand-new Optometry Program, co-chaired by Danica Marrelli, OD, FAAO, AAO Dipl, and Cecelia Koetting, OD, FAAO, DipABO.

The free, online event will feature presentations from Rachel Huckfeldt, MD, PhD, and Rachelle Lin, OD.

Twelve-week data from the Ph1b/2a AMARONE trial reveals Restoret to be well-tolerated in patients with diabetic macular edema and neovascular age-related macular degeneration.

Central retinal artery occlusion is characterized by painless, sudden vision loss in one eye, which may be a sign of an eye stroke.

These 3 participants have received their first aflibercept injection for the treatment of wet AMD.

According to the organization, GYROS results will help researchers design clinical trials for an emerging gyrate atrophy gene therapy.

Researchers at the Eye Clinic of the University Hospital Bonn (UKB) and the University of Bonn have tested a new imaging method for monitoring intermediate uveitis.

The event, being held at the El Conquistador Resort in Puerto Rico, is offering programs for ophthalmologists and optometrists.

The study further defined the relationship between delayed rod-mediated dark adaptation and the status of outer retinal bands on optical coherence tomography.

The trial will evaluate tivozanib eye drops (KHK4951), a small-molecule vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3 tyrosine kinase inhibitor (TKI), in patients in with DME.

Preliminary safety data support a favorable benefit-risk profile at both dose levels. The preliminary efficacy and safety data trending similar to or better than the OPTIC study, in which patients continue to see ongoing clinical benefit through at least 3 years.

OK-101 is the first IND clearance granted by the FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain.

A new study found that only a little over half of school-aged children participants underwent vision screening within the past two years, highlighting gaps in eye care access.

Researchers noted a study by Ruhr-University Bochum researchers provides crucial evidence that the ECM influences visual sensory motor behavior already at the retina level, without intervention of disease and/or experimental manipulation.

Sir Jules Thorn Charitable Trust's investment will support a state-of-the-art, eye health research facility, opening in 2027.

Clearside noted in a news release it intends to use the net proceeds from this offering for working capital and general corporate purposes.

Toku’s AI technology, CLAiR, has obtained CE and UKCA Marks. CLAiR provides fast, accurate, non-invasive cardiovascular disease (CVD) risk assessments using standard retinal images.

According to the company, AGTC-501 was generally safe and well-tolerated and showed improvements in visual function at the 12-month analysis. The Phase 2/3 VISTA trial for AGTC-501 in XLRP expected to begin in in the first half of 2024.

According to the company, 4D-150 was well tolerated with a favorable safety profile when evaluated through up to 48 weeks of follow-up, with no significant inflammation observed.

A team of neuroscientists at Johns Hopkins show how specialized cells signal the presence of light simultaneously in two distinct ways.

The agreement settles Zeiss’s lawsuit against Topcon’s US-based subsidiaries that had been set to start this month in US federal court for the Northern District of California.

Trial will analyze efficacy, safety of AVD-104 versus avacincaptad pegol to treat GA